drugset / Trial / NCT07162571
This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.
Phase 1/2
Not yet recruiting
17 enrolled
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to estimate the safety and the efficacy of anti-CD19/22 CAR- T cells immunotherapy for adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma.
Timeline
- Start
- 2026-01-01
- Primary completion
- 2030-12
- Completion
- 2031-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19/22 CAR-T cells | Cell therapy | 5e+07 cells | — |
| Subject | CD19/22 CAR-T cells | Cell therapy | 1.5e+08 cells | — |